SB-258,719 je lek koji deluje kao selektivni parcijalniinverzni agonist5-HT7receptora.[5] On je bio prvi identifikovani antagonist 5-HT7 receptora.[6] On se uglavnom upotrebljan u istraživanjima za demonstriranje potencijalne uloge 5-HT7 agonista kao potencijalnihanalgetika, usled njegove sposobnosti da blokira analgetičke efekte raznih 5-HT7 agonista u miše modela.[7][8][9][10]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (July 2004). „Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors”. European Journal of Pharmacology495 (2-3): 97–102. DOI:10.1016/j.ejphar.2004.05.033. PMID15249157.
↑Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ, Brown AM, Collin L, Hagan JJ, Middlemiss DN, Riley GJ, Thomas DR, Upton N (February 1998). „(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist”. Journal of Medicinal Chemistry41 (5): 655–7. DOI:10.1021/jm970519e. PMID9513592.
↑Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L (August 2011). „Potentiation of Morphine Analgesia by Adjuvant Activation of 5-HT(7) Receptors”. Journal of Pharmacological Sciences116 (4): 388–91. PMID21778664.